Journal article
Doni Bloomfield, Zhigang Lu, Aaron S. Kesselheim
British Medical Journal, vol. 377, 2022
British Medical Journal, vol. 377, 2022
Cite
Cite
APA
Click to copy
Bloomfield, D., Lu, Z., & Kesselheim, A. S. (2022). Improving the Quality of US Drug Patents Through International Awareness. British Medical Journal, 377. https://doi.org/10.1136/bmj-2021-068172
Chicago/Turabian
Click to copy
Bloomfield, Doni, Zhigang Lu, and Aaron S. Kesselheim. “Improving the Quality of US Drug Patents Through International Awareness.” British Medical Journal 377 (2022).
MLA
Click to copy
Bloomfield, Doni, et al. “Improving the Quality of US Drug Patents Through International Awareness.” British Medical Journal, vol. 377, 2022, doi:10.1136/bmj-2021-068172.
BibTeX Click to copy
@article{doni2022a,
title = {Improving the Quality of US Drug Patents Through International Awareness},
year = {2022},
journal = {British Medical Journal},
volume = {377},
doi = {10.1136/bmj-2021-068172},
author = {Bloomfield, Doni and Lu, Zhigang and Kesselheim, Aaron S.}
}
Summary: We propose and analyze a procedure the US Patent and Trademark Office (PTO) can use to improve drug patent quality by surveying parallel outcomes at other patent offices. We find that approximately 8 percent of the most important patents protecting brand-name small-molecule drugs in the United States--those listed in the FDA Orange Book--had sibling patents discontinued at the European Patent Office before the US patent issued. Some of these patents extend manufacturer statutory exclusivity in the United States by several years, including on multi-billion dollar products. We propose that the PTO give applications like these additional scrutiny.
